--Epoxomycin

(-)-Epoxomicin is a naturally occurring selective proteasome inhibitor with anti-inflammatory activity[1]. It was originally discovered in 1992 and has been shown to induce Parkinson's-like symptoms in rats when injected[1]. Derivatives of epoxomicin include carfilzomib[1].

Epoxomicin is a potent and selective proteasome inhibitor that exhibits in vivo anti-inflammatory activity[2]. It prevents IκB degradation and activation of NF-κB DNA-binding activity, suggesting that proteasome inhibition may be a viable strategy for anti-inflammation therapy[2].

Epoxomicin is an epoxyketone-containing natural product and a potent, selective, and irreversible proteasome inhibitor[4]. It is predominantly active against the chymotrypsin-like activity of the proteasome and has been shown to be an anti-inflammatory and antitumor agent, active both in vitro and in vivo[4][5].

The product is available from Abcam as a solid with a purity of > 97% and a CAS number of 134381-21-8[5]. It is soluble in DMSO to 10 mM and has a molecular weight of 554.73[5]. The product is recommended to be stored at -20°C and can be stored for up to 12 months[5].

In summary, (-)-epoxomicin is a potent and selective proteasome inhibitor with anti-inflammatory activity, originally discovered in 1992, and has been shown to be active in vitro and in vivo[1][2][4][5].

Citations:

[1] https://en.wikipedia.org/wiki/Epoxomicin

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC17900/

[3] https://pubmed.ncbi.nlm.nih.gov/10468620/

[4] https://www.medchemexpress.com/Epoxomicin.html

[5] https://www.abcam.com/products/biochemicals/epoxomicin-20s-proteasome-inhibitor-ab144598.html